TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study
Brief Summary: The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of tiotropium. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study
Brief Summary: The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of tiotropium. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.


Options:
A: Arm Label: Roflumilast; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Placebo, Roflumilast
B: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
C: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.


Options:
A: Arm Label: Placebo plus standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Standard therapy | Arm Label: Belimumab 200 mg SC plus standard therapy; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 200 mg SC, Drug: Standard therapy | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus standard therapy | Intervention Type: BIOLOGICAL; Name: Belimumab 200 mg SC; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy | Intervention Type: DRUG; Name: Standard therapy; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy, Placebo plus standard therapy
B: Arm Label: Belimumab; Type: EXPERIMENTAL; Interventions: Drug: Belimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Belimumab; Assigned to Arm(s): Belimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Arm Label: 2.; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Intervention Type: DRUG; Name: belimumab; Assigned to Arm(s): 1, 2.
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain
Brief Summary: The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.

Whether duloxetine once daily can help patients with Chronic Low Back Pain.

Patients who do not have their pain reduced by at least 30% by week 7 will be given 120 mg dose for the duration of the study. After the 13 week double blind period, patients randomized to placebo will switch to duloxetine 60 mg or 120 mg in the 41-week extension period.


Options:
A: Arm Label: DVS SR Open Label; Type: OTHER; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): DVS SR Open Label
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral tablet | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo oral tablet; Assigned to Arm(s): Placebo
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Pregabalin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain
Brief Summary: The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.

Whether duloxetine once daily can help patients with Chronic Low Back Pain.

Patients who do not have their pain reduced by at least 30% by week 7 will be given 120 mg dose for the duration of the study. After the 13 week double blind period, patients randomized to placebo will switch to duloxetine 60 mg or 120 mg in the 41-week extension period.


Options:
A: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: E; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): B | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): E
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain
Brief Summary: The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.

Whether duloxetine once daily can help patients with Chronic Low Back Pain.

Patients who do not have their pain reduced by at least 30% by week 7 will be given 120 mg dose for the duration of the study. After the 13 week double blind period, patients randomized to placebo will switch to duloxetine 60 mg or 120 mg in the 41-week extension period.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar pill | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Sugar pill; Assigned to Arm(s): Sugar pill
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients
Brief Summary: The purpose of the study is to determine the best dose of Vitamin D to give to hip fracture patients to achieve the optimal therapeutic level.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone | Arm Label: TZD placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Vitamin D placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): rosiglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): TZD placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Vitamin D placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Calcium and vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D and calcium suplementation | Intervention Type: DRUG; Name: Vitamin D and calcium suplementation; Assigned to Arm(s): Calcium and vitamin D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Brief Summary: Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.


Options:
A: Arm Label: PCI only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: human recombinant erythropoietin | Intervention Type: DRUG; Name: human recombinant erythropoietin; Assigned to Arm(s): EPO
B: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-site Evaluation of a Video Game for Adolescents and Young Adults With Cancer
Brief Summary: The purpose of this study is to determine the effects of playing the interactive video game, Re-Mission, on patient outcomes, including adherence to medical treatment regimes, self-care behaviors, quality of life, stress, communication, control, and knowledge.


Options:
A: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Intervention Type: DEVICE; Name: Electronic health record and messaging system; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: 6 months readmission rate to hospital; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-site Evaluation of a Video Game for Adolescents and Young Adults With Cancer
Brief Summary: The purpose of this study is to determine the effects of playing the interactive video game, Re-Mission, on patient outcomes, including adherence to medical treatment regimes, self-care behaviors, quality of life, stress, communication, control, and knowledge.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Health Workers Intervention | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Health Workers and Mobile Phone Intervention | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer Health Workers Intervention; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Peer Health Workers and Mobile Phone Intervention; Assigned to Arm(s): B
B: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Semi-structured, open ended interview; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.
Brief Summary: The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.


Options:
A: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: RWJ 333369 | Intervention Type: DRUG; Name: RWJ 333369; Assigned to Arm(s): 001
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 002

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial
Brief Summary: The purpose of this randomized clinical trial is to determine whether outpatient treatment is as effective and safe as inpatient treatment among low-risk patients with pulmonary embolism.


Options:
A: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
C: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment
D: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial
Brief Summary: The purpose of this randomized clinical trial is to determine whether outpatient treatment is as effective and safe as inpatient treatment among low-risk patients with pulmonary embolism.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Integration of electronic clinical decision support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integration of electronic clinical decision support; Assigned to Arm(s): Intervention
B: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
C: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A

Answer: B